Phosphagenics has announced positive results from a phase 1B clinical study using its TPM (Targeted Penetration Matrix) for the transdermal delivery of oxycodone. The trial showed that daily application of a TPM-oxycodone patch delivered therapeutic bloodstream levels of oxycodone in a reproducible, consistent and sustained manner.
Interested in Monitoring? Call 877-596-2224
Current Customers Call 877-296-6465
Patients & Other Questions Call 877-643-6179